GQ Bio Therapeutics is at the forefront of gene therapy innovation, utilizing a high-capacity gene therapy vector platform (HCAd) that allows for the efficient delivery of large and multiple genes. This advanced platform addresses significant limitations of traditional gene therapy vectors, such as their capacity and immunogenicity. HCAd vectors can carry up to 30,000 base pairs of DNA, significantly surpassing the 2,500–5,000 base pair capacity of adeno-associated vectors (AAV). This capability enables GQ Bio to develop transformative therapies aimed at prevalent diseases, particularly in the musculoskeletal field, such as osteoarthritis and intervertebral disc degeneration. The technology is designed to facilitate long-term gene expression and high transduction efficiency in various tissues, especially in joints and intervertebral discs.

The company's lead product, GQ-501, is a gene therapy candidate specifically targeting osteoarthritis, which has recently received patent protection in the United States. This therapy utilizes the HCAd platform to express therapeutic proteins that can restore joint and disc structure, inhibit inflammation, and alleviate symptoms. By enabling the affected tissues to produce these proteins following a single injection, GQ Bio aims to provide sustained symptomatic relief and potentially modify the disease's progression. This innovative approach represents a significant advancement in the treatment of musculoskeletal disorders, moving beyond conventional symptomatic treatments to offer a more effective, long-lasting solution for millions of patients.

Germany

GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium.

GQ Bio Therapeutics

Company Details